NASDAQ:ACIU - AC Immune Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.84 -0.09 (-1.01 %)
(As of 11/14/2018 04:00 PM ET)
Previous Close$8.93
Today's Range$8.50 - $9.02
52-Week Range$7.16 - $17.40
Volume40,326 shs
Average Volume92,583 shs
Market Capitalization$570.37 million
P/E Ratio-29.47
Dividend YieldN/A
Beta1.09
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Essex Bio-Technology Limited, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACIU
Previous Symbol
CUSIPN/A
Phone41-21-345-9121

Debt

Debt-to-Equity Ratio0.01
Current Ratio9.65
Quick Ratio9.65

Price-To-Earnings

Trailing P/E Ratio-29.47
Forward P/E Ratio-9.51
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.58 million
Price / Sales37.37
Cash FlowN/A
Price / CashN/A
Book Value$2.09 per share
Price / Book4.23

Profitability

EPS (Most Recent Fiscal Year)($0.30)
Net Income$-26,840,000.00
Net Margins-133.00%
Return on Equity-25.44%
Return on Assets-22.37%

Miscellaneous

Employees86
Outstanding Shares65,860,000
Market Cap$570.37 million
OptionableNot Optionable

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) announced its earnings results on Tuesday, November, 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. The company had revenue of $2.34 million for the quarter, compared to the consensus estimate of $1.71 million. AC Immune had a negative return on equity of 25.44% and a negative net margin of 133.00%. View AC Immune's Earnings History.

When is AC Immune's next earnings date?

AC Immune is scheduled to release their next quarterly earnings announcement on Tuesday, March 19th 2019. View Earnings Estimates for AC Immune.

What price target have analysts set for ACIU?

3 Wall Street analysts have issued 12 month price objectives for AC Immune's stock. Their forecasts range from $14.00 to $18.00. On average, they anticipate AC Immune's stock price to reach $16.6667 in the next twelve months. This suggests a possible upside of 88.5% from the stock's current price. View Analyst Price Targets for AC Immune.

What is the consensus analysts' recommendation for AC Immune?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AC Immune.

Has AC Immune been receiving favorable news coverage?

Press coverage about ACIU stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AC Immune earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future.

Who are some of AC Immune's key competitors?

Who are AC Immune's key executives?

AC Immune's management team includes the folowing people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 60)
  • Mr. Joerg Hornstein, Chief Financial Officer
  • Dr. Andreas Muhs Ph.D., Chief Scientific Officer (Age 56)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 47)
  • Mr. Gautam Maitra Fil. Lic, Head of Regulatory & External Affairs and Sr. Expert

When did AC Immune IPO?

(ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (7.91%), Janus Henderson Group PLC (2.53%), Artal Group S.A. (1.14%), Sphera Funds Management LTD. (0.76%), Citadel Advisors LLC (0.43%) and State of New Jersey Common Pension Fund D (0.12%).

Which major investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including Cohen Lawrence B.

Which major investors are buying AC Immune stock?

ACIU stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Sphera Funds Management LTD., Citadel Advisors LLC, Artal Group S.A., State of New Jersey Common Pension Fund D, Compagnie Lombard Odier SCmA and Renaissance Technologies LLC.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $8.84.

How big of a company is AC Immune?

AC Immune has a market capitalization of $570.37 million and generates $15.58 million in revenue each year. The company earns $-26,840,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. AC Immune employs 86 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is http://www.acimmune.com.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]


MarketBeat Community Rating for AC Immune (NASDAQ ACIU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel